• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

    9/4/24 8:00:00 AM ET
    $AVTX
    $DRRX
    $HALO
    $MESO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVTX alert in real time by email

    KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives.

    "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next phase of growth," said Helena Chaye, Ph.D., CEO of KaliVir Immunotherapeutics. "Schond's appointment is a testament to our company's maturation and readiness to elevate our financial operations. His expertise will be crucial as we advance our mission to redefine cancer treatment with oncolytic virus therapy, execute our key objectives and maximize value for our stakeholders. This strategic addition to our leadership team underscores the remarkable progress we've made this year and positions us strongly for the exciting times ahead."

    Prior to joining KaliVir, Mr. Greenway served as CFO at MindMed (NASDAQ:MNMD), where he was responsible for all aspects of corporate finance, investor relations, public relations and information technology. He previously served as CFO at Avalo Therapeutics (NASDAQ:AVTX). Earlier in his career, he held executive leadership roles at Mesoblast Ltd (NASDAQ:MESO), Halozyme Therapeutics (NASDAQ:HALO), and DURECT Corporation (NASDAQ:DRRX). His investment banking career began at Morgan Stanley, and he later became Vice President, Healthcare Desk Analyst at Barclays Capital. Throughout his career, Mr. Greenway has played a pivotal role in advising and participating in transactions totaling more than $30 billion. He also played a critical role in securing more than $1.5 billion in growth equity, debt capital and R&D funding from biopharmaceutical companies during his leadership tenures at MindMed, Avalo Therapeutics, and other life sciences organizations.

    "Throughout my career, I have made it a priority to be a part of companies looking to advance new treatment paradigms that will make a difference in the lives of patients and I'm honored to play a role in KaliVir's journey to transform cancer care," said Schond Greenway, CFO of KaliVir Immunotherapeutics. "As the company's first CFO, I look forward to leveraging my experience in biotech finance to build a strong financial infrastructure that will support KaliVir's growth and innovation. I'm excited to join a team that's not only pushing the boundaries of science but also poised to create significant value for patients and shareholders alike."

    About KaliVir Immunotherapeutics, Inc.

    KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform, Vaccinia Enhanced Template (VET™) platform, that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and enhance intravenous delivery and spread. The VET platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients' immune systems and modify the tumor microenvironment. The company's lead clinical candidate VET3-TGI is now in Phase 1 development for the treatment of incurable, solid tumors. KaliVir's oncolytic virus candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir has announced collaborations with Roche and Astellas Pharma to design and generate novel oncolytic vaccinia viruses derived from the VET™ platform. In addition, Astellas entered into a world-wide exclusive license to develop and commercialize KaliVir's initial lead clinical candidate VET2-L2 oncolytic vaccinia virus. KaliVir is currently advancing multiple therapeutic candidates toward the clinic. For more information, please visit KaliVir.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240904799827/en/

    Get the next $AVTX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AVTX
    $DRRX
    $HALO
    $MESO

    CompanyDatePrice TargetRatingAnalyst
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Halozyme Therapeutics Inc.
    $HALO
    7/10/2025$55.00Neutral
    Goldman
    Avalo Therapeutics Inc.
    $AVTX
    6/2/2025$15.00Buy
    H.C. Wainwright
    Halozyme Therapeutics Inc.
    $HALO
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    Halozyme Therapeutics Inc.
    $HALO
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    Avalo Therapeutics Inc.
    $AVTX
    3/25/2025$36.00Buy
    Stifel
    Avalo Therapeutics Inc.
    $AVTX
    3/25/2025$23.00Buy
    Jefferies
    Avalo Therapeutics Inc.
    $AVTX
    2/28/2025$48.00Overweight
    Piper Sandler
    More analyst ratings

    $AVTX
    $DRRX
    $HALO
    $MESO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      12/5/24 4:30:05 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      11/14/24 5:21:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

      4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

      8/26/24 7:00:03 PM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Brown James E was granted 96,959 shares, increasing direct ownership by 55% to 273,412 units (SEC Form 4)

      4 - DURECT CORP (0001082038) (Issuer)

      7/15/25 7:57:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Sussman Norman was granted 46,425 shares (SEC Form 4)

      4 - DURECT CORP (0001082038) (Issuer)

      7/15/25 7:56:58 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Papp Timothy M. was granted 46,659 shares, increasing direct ownership by 17% to 321,659 units (SEC Form 4)

      4 - DURECT CORP (0001082038) (Issuer)

      7/15/25 7:56:42 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mesoblast downgraded by Jefferies

      Jefferies downgraded Mesoblast from Buy to Hold

      7/18/25 8:10:38 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman resumed coverage on Halozyme Therapeutics with a new price target

      Goldman resumed coverage of Halozyme Therapeutics with a rating of Neutral and set a new price target of $55.00

      7/10/25 8:55:45 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright resumed coverage on Avalo Therapeutics with a new price target

      H.C. Wainwright resumed coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $15.00

      6/2/25 8:50:04 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

      WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors. "We are pleased to welcome Dr. Jain to Avalo's Board of Directors," said Michael Heffernan, Chairman of the Board. "Rita's extensive experience spanning clinical development, regulatory strategy, and executive leadership at multiple development-stage biopharma companies will be invaluable as we continue to advance AVTX-009, a high affinity anti-IL-1β monoclonal antibody in a Phase 2 trial for hidradenitis suppurativa (HS) and take a thought

      6/18/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Brandi L. Roberts as its Chief Financial Officer (CFO), effective June 2, 2025. In her new role, Ms. Roberts will join MindMed's executive leadership team where she will oversee all aspects of financial strategy, capital planning, accounting, investor relations and information technology as the Company advances its clinical development and commercial priorities for its lead product candidate MM120 orally disintegrating tablet (ODT) for generalized anxiety disorder (GAD

      5/27/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

      NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

      4/29/25 8:53:27 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

      SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

      12/16/24 12:08:07 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by DURECT Corporation

      SC 13G/A - DURECT CORP (0001082038) (Subject)

      11/19/24 5:10:25 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 6:23:00 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the web

      7/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

      DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO, July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all

      7/23/25 11:36:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Report Second Quarter 2025 Financial and Operating Results

      SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137779. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a

      7/22/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for POSIMIR

      Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

      2/2/21 7:24:30 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    SEC Filings

    See more
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      7/17/25 9:47:33 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Mesoblast Limited

      6-K - MESOBLAST LTD (0001345099) (Filer)

      7/14/25 9:18:36 PM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • DURECT Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DURECT CORP (0001082038) (Filer)

      7/11/25 4:30:29 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AVTX
    $DRRX
    $HALO
    $MESO
    Financials

    Live finance-specific insights

    See more
    • MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

      Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the web

      7/24/25 7:00:00 AM ET
      $MNMD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Halozyme to Report Second Quarter 2025 Financial and Operating Results

      SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137779. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a

      7/22/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Therapeutics Added to Russell 1000® Index

      SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. "Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth," said Dr. Helen To

      6/30/25 4:05:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care